Nasdaq:US$13.22 (-0.05) | HKEX:HK$21.10 (-0.20) | AIM:£2.13 (+0.1)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 29 Oct 2022

NANETS 2022:An open-label, Phase 1b/2 study of surufatinib in combination with tislelizumab in patients with advanced neuroendocrine tumors